HC Wainwright Lowers Bicara Therapeutics (NASDAQ:BCAX) Price Target to $44.00
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) had its target price lowered by research analysts at HC Wainwright from $45.00 to $44.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 369.58% from the company’s previous close. Several […]
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) had its target price lowered by research analysts at HC Wainwright from $45.00 to $44.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 369.58% from the company’s previous close. Several […]
